Jenny Ge

Cooley advised Thirty Madison, a specialty healthcare company offering high-quality virtual specialized care for patients experiencing a range of conditions, on its definitive agreement to be acquired by Remedy Meds in an all-stock transaction valued in excess of $500 million.

Cooley advised Indian conglomerate Reliance Industries on its joint venture with Meta that will build and scale enterprise artificial intelligence solutions for enterprises in India and select international markets.

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Drata, a trust management platform, on its definitive agreement to acquire SafeBase, a trust center platform designed for friction-free security reviews.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.